vs

Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and MIDDLEFIELD BANC CORP (MBCN). Click either name above to swap in a different company.

LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $19.9M, roughly 1.6× MIDDLEFIELD BANC CORP). MIDDLEFIELD BANC CORP runs the higher net margin — 26.7% vs -32.1%, a 58.9% gap on every dollar of revenue. On growth, MIDDLEFIELD BANC CORP posted the faster year-over-year revenue change (18.3% vs -4.5%). MIDDLEFIELD BANC CORP produced more free cash flow last quarter ($3.4M vs $25.0K). Over the past eight quarters, MIDDLEFIELD BANC CORP's revenue compounded faster (13.7% CAGR vs -0.1%).

LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.

Star Banc Corporation was a Cincinnati, Ohio-based regional bank holding company that acquired Firstar in 1998 and took the Firstar name; the merged bank acquired U.S. Bancorp in 2001 and took the U.S. Bancorp name. The company can trace its origins back to 1863 when it was first founded as the First National Bank of Cincinnati.

LFCR vs MBCN — Head-to-Head

Bigger by revenue
LFCR
LFCR
1.6× larger
LFCR
$31.1M
$19.9M
MBCN
Growing faster (revenue YoY)
MBCN
MBCN
+22.7% gap
MBCN
18.3%
-4.5%
LFCR
Higher net margin
MBCN
MBCN
58.9% more per $
MBCN
26.7%
-32.1%
LFCR
More free cash flow
MBCN
MBCN
$3.4M more FCF
MBCN
$3.4M
$25.0K
LFCR
Faster 2-yr revenue CAGR
MBCN
MBCN
Annualised
MBCN
13.7%
-0.1%
LFCR

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
LFCR
LFCR
MBCN
MBCN
Revenue
$31.1M
$19.9M
Net Profit
$-10.0M
$5.3M
Gross Margin
25.0%
Operating Margin
-9.9%
32.2%
Net Margin
-32.1%
26.7%
Revenue YoY
-4.5%
18.3%
Net Profit YoY
-52.0%
127.4%
EPS (diluted)
$-0.29
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LFCR
LFCR
MBCN
MBCN
Q3 25
$31.1M
$19.9M
Q2 25
$20.5M
Q1 25
$35.2M
$18.0M
Q4 24
$32.6M
$17.5M
Q3 24
$24.7M
$16.8M
Q2 24
$16.8M
Q1 24
$35.7M
$16.8M
Q4 23
$30.1M
$15.4M
Net Profit
LFCR
LFCR
MBCN
MBCN
Q3 25
$-10.0M
$5.3M
Q2 25
$6.2M
Q1 25
$-14.8M
$4.8M
Q4 24
$-6.6M
$4.8M
Q3 24
$-16.2M
$2.3M
Q2 24
$4.2M
Q1 24
$15.6M
$4.2M
Q4 23
$14.2M
$3.5M
Gross Margin
LFCR
LFCR
MBCN
MBCN
Q3 25
25.0%
Q2 25
Q1 25
28.0%
Q4 24
34.0%
Q3 24
21.8%
Q2 24
Q1 24
33.3%
Q4 23
33.0%
Operating Margin
LFCR
LFCR
MBCN
MBCN
Q3 25
-9.9%
32.2%
Q2 25
35.9%
Q1 25
-25.7%
31.9%
Q4 24
-6.0%
33.4%
Q3 24
-46.9%
16.1%
Q2 24
28.8%
Q1 24
-2.5%
29.4%
Q4 23
-4.9%
27.7%
Net Margin
LFCR
LFCR
MBCN
MBCN
Q3 25
-32.1%
26.7%
Q2 25
30.0%
Q1 25
-42.0%
26.8%
Q4 24
-20.2%
27.8%
Q3 24
-65.7%
13.9%
Q2 24
24.7%
Q1 24
43.8%
24.9%
Q4 23
47.2%
23.0%
EPS (diluted)
LFCR
LFCR
MBCN
MBCN
Q3 25
$-0.29
$0.65
Q2 25
$0.76
Q1 25
$-0.47
$0.60
Q4 24
$-0.25
$0.60
Q3 24
$-0.53
$0.29
Q2 24
$0.52
Q1 24
$0.42
$0.51
Q4 23
$0.39
$0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LFCR
LFCR
MBCN
MBCN
Cash + ST InvestmentsLiquidity on hand
$18.9M
Total DebtLower is stronger
$136.0M
Stockholders' EquityBook value
$-10.5M
$224.1M
Total Assets
$235.2M
$2.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LFCR
LFCR
MBCN
MBCN
Q3 25
$18.9M
Q2 25
Q1 25
$5.4M
Q4 24
$9.5M
Q3 24
Q2 24
Q1 24
Q4 23
Total Debt
LFCR
LFCR
MBCN
MBCN
Q3 25
$136.0M
Q2 25
Q1 25
$124.9M
Q4 24
$111.3M
Q3 24
$106.3M
Q2 24
Q1 24
$97.1M
Q4 23
$92.9M
Stockholders' Equity
LFCR
LFCR
MBCN
MBCN
Q3 25
$-10.5M
$224.1M
Q2 25
$216.1M
Q1 25
$2.2M
$213.8M
Q4 24
$15.4M
$210.6M
Q3 24
$-3.9M
$210.7M
Q2 24
$206.8M
Q1 24
$17.7M
$205.6M
Q4 23
$1.4M
$205.7M
Total Assets
LFCR
LFCR
MBCN
MBCN
Q3 25
$235.2M
$2.0B
Q2 25
$1.9B
Q1 25
$237.7M
$1.9B
Q4 24
$255.4M
$1.9B
Q3 24
$246.8M
$1.9B
Q2 24
$1.8B
Q1 24
$246.2M
$1.8B
Q4 23
$245.8M
$1.8B
Debt / Equity
LFCR
LFCR
MBCN
MBCN
Q3 25
Q2 25
Q1 25
56.05×
Q4 24
7.20×
Q3 24
Q2 24
Q1 24
5.49×
Q4 23
65.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LFCR
LFCR
MBCN
MBCN
Operating Cash FlowLast quarter
$1.8M
$4.8M
Free Cash FlowOCF − Capex
$25.0K
$3.4M
FCF MarginFCF / Revenue
0.1%
17.0%
Capex IntensityCapex / Revenue
5.6%
7.2%
Cash ConversionOCF / Net Profit
0.91×
TTM Free Cash FlowTrailing 4 quarters
$-16.8M
$32.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LFCR
LFCR
MBCN
MBCN
Q3 25
$1.8M
$4.8M
Q2 25
$4.8M
Q1 25
$1.2M
$8.0M
Q4 24
$-6.1M
$17.5M
Q3 24
$-613.0K
$6.0M
Q2 24
$3.4M
Q1 24
$-1.4M
$5.4M
Q4 23
$1.3M
$7.7M
Free Cash Flow
LFCR
LFCR
MBCN
MBCN
Q3 25
$25.0K
$3.4M
Q2 25
$4.2M
Q1 25
$-4.3M
$7.7M
Q4 24
$-8.6M
$16.7M
Q3 24
$-4.0M
$5.8M
Q2 24
$3.3M
Q1 24
$-7.8M
$5.3M
Q4 23
$-3.0M
$7.7M
FCF Margin
LFCR
LFCR
MBCN
MBCN
Q3 25
0.1%
17.0%
Q2 25
20.5%
Q1 25
-12.1%
42.9%
Q4 24
-26.3%
95.6%
Q3 24
-16.3%
34.7%
Q2 24
19.3%
Q1 24
-21.8%
31.9%
Q4 23
-9.9%
50.1%
Capex Intensity
LFCR
LFCR
MBCN
MBCN
Q3 25
5.6%
7.2%
Q2 25
3.0%
Q1 25
15.5%
1.5%
Q4 24
7.5%
4.4%
Q3 24
13.9%
1.0%
Q2 24
0.6%
Q1 24
17.8%
0.5%
Q4 23
14.1%
0.2%
Cash Conversion
LFCR
LFCR
MBCN
MBCN
Q3 25
0.91×
Q2 25
0.78×
Q1 25
1.66×
Q4 24
3.60×
Q3 24
2.57×
Q2 24
0.81×
Q1 24
-0.09×
1.31×
Q4 23
0.09×
2.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LFCR
LFCR

Transferred At Point In Time$26.6M85%
Transferred Over Time$4.5M15%

MBCN
MBCN

Segment breakdown not available.

Related Comparisons